Virtus Biotech ETF
BBP
14 hedge funds and large institutions have $3.68M invested in Virtus Biotech ETF in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
34% more capital invested
Capital invested by funds: $2.74M → $3.68M (+$938K)
17% more funds holding
Funds holding: 12 → 14 (+2)
2.83% more ownership
Funds ownership: 15.74% → 18.58% (+2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$500K |
| 2 |
Goldman Sachs
New York
|
+$376K |
| 3 |
IFG
Independent Financial Group
San Diego,
California
|
+$254K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$228K |
| 5 |
Morgan Stanley
New York
|
+$220K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$540K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$26K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$17.5K |
| 4 |
FWM
Focused Wealth Management
Newburgh,
New York
|
-$11.6K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$8.71K |
BBP Hedge Fund Activity: Q1 2024 in Review
14 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q1 2024, worth a combined $3.68M — up 34% from $2.74M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BBP positions and 3 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Raymond James Financial Services Advisors, opening a new position worth an estimated $500K. The largest seller was Susquehanna International Group, cutting an estimated $540K.
- 14 institutional investors held Virtus Biotech ETF (BBP) as of Q1 2024, up from 12 in Q4 2023.
- Funds reported $3.68M of Virtus Biotech ETF stock for Q1 2024, up 34% quarter-over-quarter.
- 5 funds opened new Virtus Biotech ETF positions in Q1 2024 and 3 closed out, a net change of +2 holders.
- The largest Virtus Biotech ETF buyer in Q1 2024 was Raymond James Financial Services Advisors, an estimated $500K added.
- The largest Virtus Biotech ETF seller in Q1 2024 was Susquehanna International Group, an estimated $540K sold.
Based on aggregated 13F filings for Q1 2024.